There are currently 50 active clinical trials seeking participants for Cholangiocarcinoma research studies. The states with the highest number of trials for Cholangiocarcinoma participants are California, Texas, Michigan and Ohio.
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02757859
Recruiting
This randomized clinical trial studies how well high volume washing of the abdomen works in increasing survival after surgery in patients with pancreatic cancer that can be removed by surgery. High volume washings may remove free floating cancers present after surgery and help prolong survival in patients with pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Case Western Reserve University, Cleveland, Ohio +1 locations
Conditions: Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma, Cholangiocarcinoma, Duodenal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Periampullary Adenocarcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm
Register for Updates
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
NCT04792463
Recruiting
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screen... Read More
Gender:
All
Ages:
All
Trial Updated:
10/23/2023
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma, Mesothelioma, Hepatocellular Carcinoma, Cholangiocarcinoma, Meningioma Atypical
Register for Updates
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
NCT03801083
Recruiting
This is a Phase 2 study to evaluate the efficacy, using objective response rate, of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous Tumor Infiltrating Lymphocytes (TIL) and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic biliary tract cancer. These are low-incidence cancers carry a poor prognosis. Participants will include patients with biliary tract cancers (BTC), including cholangiocarcinoma (both intrahepatic and ext... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/21/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Neoplasms
Register for Updates
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: UCLA Medical Center, Santa Monica, California +86 locations
Conditions: Cholangiocarcinoma
Register for Updates
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
NCT04645160
Recruiting
Background: Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few treatment options and poor survival. Researchers want to see if a new drug can stop or slow CCA growth. Objective: To find the safest and most effective dose of tivozanib to treat CCA and learn its overall response rate. Eligibility: Adults ages 18 and older with CCA not removable with surgery and have been treated with at least one type of chemotherapy. Design: Participants will be sc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
Register for Updates
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
NCT05007106
Recruiting
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Alaska Womens Cancer Care ( Site 1016), Anchorage, Alaska +71 locations
Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Register for Updates
A Study of SGN-B7H4V in Advanced Solid Tumors
NCT05194072
Recruiting
This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much SGN-B7H4V... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: University of Colorado Hospital / University of Colorado, Aurora, Colorado +18 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Adenoid Cystic Carcinoma
Register for Updates
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
NCT04068194
Recruiting
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California +14 locations
Conditions: Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Cholangiocarcinoma, Gallbladder Carcinoma
Register for Updates
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
NCT01915225
Recruiting
Background: - Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC). Objectives: - To collect tissue samples for use in studying new ways to treat tumors. Eligibility: Adults 18 years and o... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Colorectal Neoplasms, Gastric Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Pancreas Cancer
Register for Updates
M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
NCT05286814
Recruiting
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug M9241 can improve the treatment. The drug triggers the immune system to fight cancer. Objective: To see if treatment with HAIPs to deliver liver-directed chemotherapy in combination with M9241 is effective for certain cancers. Eligibility: People aged 18 and older who have cancer of the bile ducts that is only in the liver,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer, Colorectal Neoplasms, Cholangiocarcinoma, Intrahepatic Bile Duct Cancer, Bile Duct Cancer, Bile Duct Neoplasms
Register for Updates
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
NCT04145141
Recruiting
Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments. Objective: To better understand liver cancer. Eligibility: People ages 18 and older who have liver cancer and had or are planning to have immune therapy Design: Participants will be screened with a review of their med... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: University of California, San Diego (UCSD), La Jolla, California +6 locations
Conditions: Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma
Register for Updates
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
NCT05848739
Recruiting
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +4 locations
Conditions: Breast Cancer Metastatic, Pancreatic Cancer, NSCLC, Metastatic, Synovial Sarcoma, Colon Cancer, Metastatic Colon Cancer, Melanoma Recurrent, Metastatic Skin Cancer, Melanoma Stage IV, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Cholangiocarcinoma, Ovarian Cancer, Metastatic Melanoma, Hepatocellular Carcinoma
Register for Updates